Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Treasurer of the State of North Carolina

Treasurer of the State of North Carolina raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 638,979 shares of the biopharmaceutical company's stock after acquiring an additional 6,980 shares during the quarter. Treasurer of the State of North Carolina owned approximately 0.05% of Gilead Sciences worth $59,022,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of GILD. HHM Wealth Advisors LLC increased its stake in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences during the 4th quarter valued at approximately $28,000. Decker Retirement Planning Inc. purchased a new position in Gilead Sciences in the 4th quarter worth approximately $29,000. Crews Bank & Trust bought a new position in Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC grew its holdings in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Up 2.9 %

Gilead Sciences stock traded up $3.04 during mid-day trading on Monday, reaching $106.67. 2,532,004 shares of the company were exchanged, compared to its average volume of 7,481,789. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The business has a fifty day moving average of $108.34 and a 200 day moving average of $96.89. The firm has a market cap of $132.82 billion, a P/E ratio of 288.30, a PEG ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were given a $0.79 dividend. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.96%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Bank of America increased their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 142,180 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This represents a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 302,785 shares of company stock worth $30,503,250. Company insiders own 0.16% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.